CEO Total Pay
$18.5M
FY2022 Summary Compensation, well above median
TECH FY2022 SEC EDGAR DEF 14A
BIO-TECHNE Corp CEO pay ratio
The CEO earned $18.5M in FY2022 against median worker pay of $105,484 · Chemicals & Pharmaceuticals.
- State
- MN
- Filing date
- 2023-09-13
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2022
Data updated August 2026
CEO-to-worker pay ratio
175:1
High (Scale: 0–1000:1)
CEO pay
$18.5M
Median worker
$105,484
Latest filing FY2022. This company's newest DEF 14A on file is for FY2022, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
BIO-TECHNE Corp reported a 175:1 CEO-to-worker pay ratio in FY2022 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 175:1
- FY2022 disclosed
- CEO total
- $18.5M
- Summary Compensation Table total
- Median worker
- $105,484
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2022
A component-level pay breakdown is not reported in BIO-TECHNE Corp's structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
175:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$18.5M
Companies in Industry
168
vs. Industry Median
Above
BIO-TECHNE Corp: STEEP · PEAK pay ratio
BIO-TECHNE Corp disclosed 175:1 CEO-to-worker pay and $18.5M CEO total in FY2022. the CEO earned 175× the median employee ($105,484) in FY2022.
Median employee $105,484 (HIGH-MED); STEEP · PEAK stamps put about 175 median-wage years per CEO year.
Pay Ratio
175:1
Elevated vs. peers
What FY2022 shows for BIO-TECHNE Corp
BIO-TECHNE Corp disclosed 175:1 CEO-to-worker pay and $18.5M CEO total in FY2022. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; BIO-TECHNE Corp's $18.5M CEO total is above the $7.9M industry median CEO pay.
BIO-TECHNE Corp stamps STEEP · PEAK · HIGH-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2022
- Total Compensation
- $18.5M
- Median Employee Pay
- $105,484
- Pay Ratio
- 175:1
- Filing Date
- 2023-09-13
Company Info
- Ticker
- TECH
- CIK
- 842023
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- MN
SEC EDGAR DEF 14A for CIK 842023, FY2022. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. BIO-TECHNE Corp disclosed 175:1 CEO-to-worker pay and $18.5M CEO total in FY2022.
Read with BIO-TECHNE Corp
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps STEEP · PEAK · HIGH-MED.
Bentley Systems Inc · PEAK
ABS(ceo_total_comp) peer at $18.4M (Δ $19K lighter vs BIO-TECHNE Corp); STEEP · HIGH-MED vs this page's STEEP · PEAK · HIGH-MED.
Sekisui House U.S., Inc. · PEAK
ABS(ceo_total_comp) peer at $18.5M (Δ $83K heavier vs BIO-TECHNE Corp); STEEP · HIGH-MED vs this page's STEEP · PEAK · HIGH-MED.
Stryker Corp · PEAK
ABS(ceo_total_comp) peer at $18.6M (Δ $104K heavier vs BIO-TECHNE Corp); STEEP · HIGH-MED vs this page's STEEP · PEAK · HIGH-MED.
Cardinal Health Inc · PEAK
ABS(ceo_total_comp) peer at $18.6M (Δ $108K heavier vs BIO-TECHNE Corp); STEEP · PAR-MED vs this page's STEEP · PEAK · HIGH-MED.
Chemicals & Pharmaceuticals benchmark
BIO-TECHNE Corp stamps STEEP · PEAK · HIGH-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · STEEP
See where STEEP · PEAK packages sit on the national leaderboard after reading BIO-TECHNE Corp.
Comp structure · PEAK
BIO-TECHNE Corp's PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for BIO-TECHNE Corp (CIK 842023), FY2022. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.